Clinical trial
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy…
NCT00407459 · Armando Santoro, MD, Other · Completed
Key facts
| NCT number | NCT00407459 |
|---|---|
| Title | Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma |
| Official title | Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Malignant Pleural Mesothelioma |
| Lead sponsor | Armando Santoro, MD, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Pemetrexed, Carboplatin |
| Enrollment | 77 |
| Start date | Sep 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Dec 5, 2006 |
| Last update posted | Sep 2, 2011 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: